Royalty Report: Drugs, Arthritis, Therapeutic – Collection: 210030


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Arthritis
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 210030

License Grant
The Belgium Licensor entered into an exclusive license agreement with Japanese Licensee for the development and commercialization of anti-TNF alpha Nanobody, ozoralizumab, for the treatment of RA in Japan. The Licensee will be responsible for the development, registration and commercialization of ozoralizumab.
License Property
Ozoralizumab is a TNF alpha blocker being developed for the treatment of auto-immune disorders with an initial focus on RA.
Field of Use
The Japanese Licensee is planning to initiate a Phase III trial in RA patients in Japan with ozoralizumab in 2018.

IPSCIO Record ID: 210065

License Grant
The Belgium Licensor granted the China Licensee an exclusive, royalty-bearing license to develop and commercialize the anti-TNF alpha Nanobody, ozoralizumab, and certain other anti-TNF alpha Nanobodies in Greater China for all indications, including rheumatiod arthritis.
License Property
The Licensors anti-TNF alpha Nanobody, ozoralizumab, targets RA, a progressive inflammatory disease of the joints and surrounding tissues.
Field of Use
The Licensee will be responsible for the registration and commercialization in Greater China of licensed products.

IPSCIO Record ID: 286023

License Grant
The Licensor of England grants a right and license to develop, make, have made, use, offer for sale, sell, have sold, import and export Licensed Products for use in the Field in the Territory.  

The license s exclusive or non-exclusive on a patent by patent basis.

License Property
Licensor has a product, known as Cxx-870, which contains a recombinant humanized pegylated Fab’ antibody fragment which binds to TNF alpha, or Tumor Necrosis Factor? alpha.

Licensed Product means any product that contains or comprises an Antibody, or any chemically modified Antibody, which recognizes TNF alpha. For the avoidance of doubt, Licensed Product shall not include non-Antibody inhibitors of TNF alpha.

The patents are titled Multichain Polypeptides or Proteins and Processes: for their Production;
Recombinant Antibody; Humanized Antibodies; Protein Expression System;  Process for obtaining Antibodies; Monovalent Antibody Fragments;  and, Biological Products.

Field of Use
Field means the prevention, treatment, diagnosis or control of all diseases or conditions in humans or animals; provided, however, that with respect to CDP-571, the Field shall not include the prevention, treatment, diagnosis or control of any diseases or conditions other than rheumatoid arthritis.

IBD Indication means the prevention, treatment or control of Crohn’s Disease and/or ulcerative colitis in humans and/or animals.

RA Indication means the prevention, treatment or control of rheumatoid arthritis in humans.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.